Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by Security National Bank of SO Dak

Security National Bank of SO Dak raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,385 shares of the company’s stock after acquiring an additional 620 shares during the period. Security National Bank of SO Dak’s holdings in Teva Pharmaceutical Industries Limited were worth $578,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of TEVA. Capital Research Global Investors grew its stake in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the period. Franklin Resources Inc. grew its stake in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after acquiring an additional 6,685,844 shares during the period. FMR LLC grew its stake in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after acquiring an additional 6,115,853 shares during the period. Capital World Investors grew its stake in Teva Pharmaceutical Industries Limited by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after acquiring an additional 3,268,200 shares during the period. Finally, Alliancebernstein L.P. grew its stake in Teva Pharmaceutical Industries Limited by 32.3% in the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after acquiring an additional 2,782,257 shares during the period. 56.75% of the stock is owned by hedge funds and other institutional investors.

TEVA has been the subject of a number of research analyst reports. Mizuho raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and boosted their target price for the company from $25.00 to $30.00 in a research note on Thursday, June 15th. Royal Bank Of Canada set a $38.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Friday, June 16th. Oppenheimer Holdings, Inc. set a $41.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Tuesday, June 27th. BidaskClub raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Finally, Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $32.27 target price for the company in a research note on Tuesday, July 11th. Five research analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $27.63.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 0.13% during mid-day trading on Tuesday, reaching $15.75. The company had a trading volume of 6,877,205 shares. The company’s market capitalization is $16.00 billion. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $45.14. The stock has a 50 day moving average price of $16.87 and a 200 day moving average price of $26.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.25 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.26 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.085 per share. The ex-dividend date was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 2.16%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by Security National Bank of SO Dak” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/10/10/teva-pharmaceutical-industries-limited-teva-shares-bought-by-security-national-bank-of-so-dak.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit